Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1990 • 451 citations

The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects

1990 • 367 citations

Genetic polymorphism of S-mephenytoin hydroxylation

1989 • 292 citations

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1989 • 292 citations

Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-Hydroxylation

1993 • 286 citations

Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

1993 • 214 citations

Recent Developments in Hepatic Drug Oxidation

1990 • 189 citations

Inhibitors of imipramine metabolism by human liver microsomes.

1992 • 165 citations

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1991 • 162 citations

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1991 • 139 citations

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

1989 • 116 citations

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes

1985 • 91 citations

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

1992 • 89 citations

Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

1986 • 79 citations

Active Metabolites of Neuroleptic Drugs

1982 • 76 citations

Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline

1992 • 68 citations

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1991 • 66 citations

Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

1989 • 63 citations

Limitation to the use of the urinary S‐/R‐mephenytoin ratio in pharmacogenetic studies.

1991 • 50 citations

Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: Evidence for different stereoselectivities at D1 and D2 receptors in rat brain

1988 • 45 citations

GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin

1988 • 44 citations

Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma

1995 • 39 citations

Determination of Thioridazine Enantiomers in Human Serum by Sequential Achiral and Chiral High-Performance Liquid Chromatography

1993 • 32 citations

Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

1993 • 30 citations

A Preliminary Neuroendocrine Study with Buspirone in Major Depression

1994 • 29 citations

Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat

1993 • 27 citations

Synthesis, Isolation, and Characterization of Two Stereoisomeric Ring Sulfoxides of Thioridazine

1983 • 24 citations

Thioridazine toxicity--an experimental cardiovascular study of thioridazine and its major metabolites in overdose.

1985 • 24 citations

Artifacts in the analysis of thioridazine and other neuroleptics

1993 • 20 citations

Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.

1984 • 19 citations

Light-Induced Racemization

1991 • 17 citations

Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.

1989 • 12 citations

Report on the workshop ?molecular basis of polymorphic drug oxidation in man?, Otzenhausen, 1983

1984 • 7 citations